Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Teva
Boehringer Ingelheim
Deloitte
UBS
Fish and Richardson
McKinsey
Farmers Insurance
Citi
Baxter

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022405

« Back to Dashboard

NDA 022405 describes CAPRELSA, which is a drug marketed by Genzyme Corp and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the CAPRELSA profile page.

The generic ingredient in CAPRELSA is vandetanib. Two suppliers are listed for this compound. Additional details are available on the vandetanib profile page.
Summary for 022405
Tradename:CAPRELSA
Applicant:Genzyme Corp
Ingredient:vandetanib
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022405
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAPRELSA vandetanib TABLET;ORAL 022405 NDA AstraZeneca Pharmaceuticals LP 0310-7820 N 0310-7820-30
CAPRELSA vandetanib TABLET;ORAL 022405 NDA AstraZeneca Pharmaceuticals LP 0310-7840 N 0310-7840-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Apr 6, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 6, 2018
Regulatory Exclusivity Use:TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
Patent:➤ Try a Free TrialPatent Expiration:Aug 8, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jun 27, 2022Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 022405

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cipla
Boehringer Ingelheim
Moodys
Colorcon
McKinsey
US Army
Queensland Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot